- Scrip Originals
Brought to you by
AZ divests remaining Zomig rights to Grunenthal
07 Jun 2017
AstraZeneca PLC granted Grunenthal GMBH global rights (excluding Japan) to its marketed migraine drug Zomig (zolmitriptan).
- Marketing (Licensing)
Already a Biomedtracker subscriber? You have access to the full deal record through your subscription
Want to become a subscriber? Subscribers get more deal details, updates, deal financials and deal products.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com